Sort
10,766 grants matching “checkpoint inhibitor”
Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting
$485,385Young J. Kim · Vanderbilt University Medical Center · R01 · FY2018 · DE
Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer
$485,357Deborah W Knapp · Purdue University · U01 · FY2024 · CA
Targeting Autophagy in Hereditary Breast Cancer
$485,161Bing Xia · Rbhs -Cancer Institute Of New Jersey · R01 · FY2015 · CA
Immunogen design and testing
$485,034Barton F Haynes · University Of Pennsylvania · P01 · FY2019 · AI
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$484,976Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA
Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules
$484,762Trachette Jackson · University Of Michigan At Ann Arbor · U01 · FY2023 · CA
Mechanistic analyses of a novel RNA polymerase I transcription checkpoint
$484,599Marikki Laiho · Johns Hopkins University · R01 · FY2018 · GM
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
$484,410Judith S Leopold · University Of Michigan At Ann Arbor · R01 · FY2021 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
$484,410Judith S Leopold · University Of Michigan At Ann Arbor · R01 · FY2019 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
$484,410Judith S Leopold · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer
$484,365Nupam P Mahajan · Washington University · R01 · FY2025 · CA
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer
$484,364Nupam P Mahajan · Washington University · R01 · FY2023 · CA
Lung Resident Mesenchymal Cells in the Pre-Metastatic Niche Formation
$484,308Guangwen Ren · Jackson Laboratory · R01 · FY2021 · CA
Lung Resident Mesenchymal Cells in the Pre-Metastatic Niche Formation
$484,308Guangwen Ren · Jackson Laboratory · R01 · FY2025 · CA
FEEDBACK CONTROL OF THE CELL CYCLE
$484,139Harvard University · R37 · FY2002 · GM
Biochemical Studies of Human DNA Polymerase Delta
$484,099New York Medical College · R01 · FY2004 · GM
Preclinical development and clinical monitoring of adoptive immune therapy
$483,898Jeremy Rose · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
Chitinase-3-like-1 mediated immunosuppression in Glioblastoma
$483,859Baoli Hu · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Project 2: Combined CAR-T cell therapy
$483,710Gianpietro Dotti · Univ Of North Carolina Chapel Hill · P50 · FY2023 · CA
Non-coding RNA regulation of Myeloid Cells
$483,706Jorge Henao-Mejia · University Of Pennsylvania · R01 · FY2024 · CA
Targeting autophagy to enhance immune checkpoint inhibition
$483,579Ravi K Amaravadi · Wistar Institute · P50 · FY2025 · CA
TLR Agonist Nano-Immune Therapy for Peritoneal Metastases
$483,556Rita Elena Serda · University Of New Mexico Health Scis Ctr · R01 · FY2024 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$483,484Periasamy Selvaraj · Emory University · R01 · FY2018 · CA
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
$483,451Ronald M. Evans · Salk Institute For Biological Studies · P01 · FY2024 · CA
Estrogen Suppression as a Strategy to Enhance Immunotherapy Efficacy in EGFR-Mutated Non-Small Cell Lung Cancer
$483,395Joseph Nicholas Bodor · Research Inst Of Fox Chase Can Ctr · R21 · FY2024 · CA